CAR T-Cell Therapy Results in Remission for Myeloma Patients
In a study posted online by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer.
Latest News on CAR T-Cell Therapy for Multiple Myeloma
How can CAR T-cell therapy be used to treat multiple myeloma, and what is the latest in CAR T-cell research? Is it getting closer to being an approved treatment option? What are we learning from clinical trials? And finally, what should patients know?
Multiple Myeloma Roundtable: Immunotherapies & MRD Debate
Each year during the ASH Annual Meeting & Exposition, Patient Power brings together several of the world’s leading experts in multiple myeloma for a roundtable discussion of the latest myeloma research and news. Hear from three renowned experts and Patient Power co-founder Andrew Schorr as they discuss the state of multiple myeloma treatment today including advances in immunotherapy, new promising drug options, the role of minimal residual disease (MRD) testing in determining treatment paths, and other important topics including disparities in multiple myeloma care.
It’s All About the Antibodies! How mAbs work in Multiple Myeloma
"To understand how a monoclonal antibody works first you need to know what an antigen is. An antigen is a molecule that is able to generate antibodies in our immune system." - Read this review by Cindy Chmielewski on the mechanism of action (how they work) of each type of antibody.